HALO Halozyme Therapeutics Inc.

19.06
-0.41  -2%
Previous Close 19.47
Open 19.45
Price To Book 11.41
Market Cap 2,793,044,585
Shares 146,539,590
Volume 2,403,866
Short Ratio
Av. Daily Volume 1,715,225
Stock charts supplied by TradingView

NewsSee all news

  1. Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of

  2. Bernadette Connaughton Appointed to Syneos Health Board of Directors

    MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial

  3. Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it

  4. Halozyme Reports Third Quarter 2019 Results

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities

  5. Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug delivery technology. In order

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data November 4, 2019 did not meet primary endpoint.
HALO-301
Pancreatic cancer
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Cholangiocarcinoma
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer
FDA approval announced February 28, 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
sBLA filing announced July 12, 2019. PDUFA estimate May 12, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 1 trial to commence 1Q 2020.
ARGX-117
Autoimmune diseases
Phase 1 data due YE 2019.
Efgartigimod (ARGX-113) and Enhanze

Latest News

  1. Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of

  2. Bernadette Connaughton Appointed to Syneos Health Board of Directors

    MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial

  3. Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it

  4. Halozyme Reports Third Quarter 2019 Results

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities

  5. Halozyme Announces Actions To Focus Strategy On ENHANZE® Drug Delivery Technology

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug delivery technology. In order

  6. Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment

  7. Halozyme To Participate In 2019 Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 23, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the 2019 Cantor Global Healthcare

  8. Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology

    SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study